Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04276636|
Recruitment Status : Unknown
Verified October 2020 by Second Affiliated Hospital of Wenzhou Medical University.
Recruitment status was: Not yet recruiting
First Posted : February 19, 2020
Last Update Posted : October 14, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
Aims:Prospectively observe the effects of Caltrate supplementation on the chronic course of Crohn's disease patients, analyze whether the effect of Caltrate on CD patients is affected by factors such as disease site, disease activity, treatment, etc.Provide a certain theoretical basis for "precision treatment" for CD patients in the future.
Design：It is a prospective cohort study. Investigators include a total of 60 participants with CD according to the inclusion and exclusion criteria, and divide them into two groups to assess their initial disease activity and detect related indicators. At the same time，Investigators detect the Vitamin D Gene gene polymorphisms in all participants.One group is given Caltrate 0.6g per day orally, and the control group do not intervene. After 12 months, re-evaluate the disease activity and retest the relevant indicators, and use statistical methods to analyze whether Caltrate supplementation treatment can increase the serum 25 (OH) D level of CD participants, improve the condition of CD participants,relationship with Vitamin D Gene Polymorphism，and analyze the effect of Caltrate on participants with CD is affected by factors such as disease site, disease activity, and treatment.
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease Vitamin D Deficiency Vitamin D Supplement||Drug: Caltrate Pill||Early Phase 1|
- The research can be started only after approval by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University.
- According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease" formulated by the Beijing Conference in 2018 as a standard, patients with clear diagnosis of CD are collected. Exclusion criteria included pregnancy, breastfeeding, liver and kidney dysfunction, concurrent autoimmune diseases, and use of antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes.
- Assess disease activity of CD participants based on the "Simplified Crohn's disease Activity Score".
- General information about participants with CD is collected.
- Detection of VDR gene polymorphisms using Snapshot technology.
- Serum C-reactive protein, erythrocyte sedimentation rate, white blood cells, albumin, creatinine, alanine aminotransferase, calcium and phosphorus levels are measured.
- The level of serum 25 (OH) D of participants is detected.
- Develop a treatment plan for participants.
- Participants are divided into two groups, one group is given oral Caltrate 0.6g / d, and the other group did not intervene.
- The above serum indicators are re-measured in the 12th month, and the condition of CD participants is also evaluated.
Follow-up for 12 months. By comparing the above indicators, observe that in the Han population:
- Can Caltrate supplementation increase serum 25 (OH) D levels in patients with CD?
- Can Caltrate supplementation improve the condition of patients with CD?
- whether vitamin D gene polymorphisms affect the efficacy of Caltrate supplementation therapy?
- Analyze whether the effect of Caltrate on CD patients is affected by factors such as disease site, disease activity, treatment, etc ..
- Through statistical analysis, comprehensive analysis of the effectiveness and safety of Caltrate supplementation in Han patients with CD, and its relationship with vitamin D gene polymorphisms, providing a theoretical basis for further "precise treatment" intervention in inflammatory bowel disease.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||60 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency，a Prospective Cohort Study|
|Estimated Study Start Date :||October 2020|
|Estimated Primary Completion Date :||March 2021|
|Estimated Study Completion Date :||March 2021|
This group of patients are going to supplemented with Caltrate 0.6 g / d orally.
Drug: Caltrate Pill
Vitamin D-deficient CD patients are divided into two groups, one group is given orally with Caltrate Pill 0.6 g / d, while the other group do not interfere.
No Intervention: Control
The other group do not interfere.
- Serum 25 (OH) D level [ Time Frame: 1year ]Because serum 25 (OH) D levels are relatively stable, they are considered the most reliable indicator of vitamin D status.
- White blood cell count [ Time Frame: 1year ]White blood cell count can be used to reflect the degree of inflammation in the body
- erythrocyte sedimentation rate [ Time Frame: 1year ]ESR can be used to reflect the degree of inflammation in the body.
- C-reactive protein. [ Time Frame: 1year ]C-reactive protein can be used to reflect the degree of inflammation in the human body
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||Child, Adult, Older Adult|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||Yes|
- Clearly diagnosed patients with CD
- Vitamin D deficiency (<= 20ng / ml)
- Pregnancy, lactation
- Liver and kidney insufficiency
- Co-morbid with other autoimmune diseases
- Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes
- Vitamin D level is normal or high
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04276636
|Contact: Xia sheng long, Masterfirstname.lastname@example.org|
|Wenzhou, Zhejiang, China, 325000|
|Principal Investigator:||Xia Xia long, Master||Second Affiliated Hospital of Wenzhou Medical University|
|Responsible Party:||Second Affiliated Hospital of Wenzhou Medical University|
|Other Study ID Numbers:||
|First Posted:||February 19, 2020 Key Record Dates|
|Last Update Posted:||October 14, 2020|
|Last Verified:||October 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Undecided|
|Plan Description:||Data sets will be made available on relevant requests and in accordance with journal guidelines when publishing results from this study.|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
Vitamin D Deficiency
Inflammatory Bowel Diseases
Digestive System Diseases
Molecular Mechanisms of Pharmacological Action